ACAD
40.19
-0.63
-1.54%
AEMD
8.74
+0.11
+1.27%
APRI
1.64
+0.02
+1.23%
ARNA
3.985
-0.025
-0.623%
ATEC
1.36
0.00
0.00%
CNAT
5.46
+0.11
+2.06%
CRXM
0.49
+0.02
+5.15%
CYTX
0.732
+0.043
+6.1956%
DXCM
71.27
-0.37
-0.52%
GNMK
9.37
+0.11
+1.19%
HALO
17.68
-0.14
-0.79%
ILMN
208.62
-0.85
-0.41%
INNV
0.153
+0.003
+1.6667%
INO
8.58
+0.19
+2.26%
ISCO
0.05
0.00
0.00%
ISIS
66.71
-1.01
-1.49%
LGND
88.15
+0.89
+1.02%
LPTN
0.291
-0.009
-3.032%
MBVX
2.26
-0.08
-3.42%
MEIP
1.89
-0.02
-1.05%
MNOV
3.95
0.00
0.00%
MRTX
36.18
+2.43
+7.20%
MSTX
0.54
+0.03
+5.70%
NBIX
42.76
-0.18
-0.42%
NUVA
49.62
+0.84
+1.72%
ONCS
0.233
0.00
0.00%
ONVO
4.96
+0.17
+3.55%
OREX
4.92
-0.01
-0.20%
OTIC
24.33
-0.13
-0.53%
QDEL
22.24
-0.17
-0.76%
RCPT
164.83
-0.82
-0.50%
RGLS
13.58
-0.05
-0.37%
RMD
58.65
+0.55
+0.95%
SCIE
0.018
0.00
0.00%
SPHS
1.11
+0.03
+2.78%
SRNE
13.8
+0.76
+5.83%
TROV
11
-0.19
-1.70%
VICL
0.955
+0.033
+3.534%
VOLC
17.99
0.00
0.00%
ZGNX
1.49
+0.02
+1.36%
ACAD
40.19
-0.63
-1.54%
AEMD
8.74
+0.11
+1.27%
APRI
1.64
+0.02
+1.23%
ARNA
3.985
-0.025
-0.623%
ATEC
1.36
0.00
0.00%
CNAT
5.46
+0.11
+2.06%
CRXM
0.49
+0.02
+5.15%
CYTX
0.732
+0.043
+6.1956%
DXCM
71.27
-0.37
-0.52%
GNMK
9.37
+0.11
+1.19%
HALO
17.68
-0.14
-0.79%
ILMN
208.62
-0.85
-0.41%
INNV
0.153
+0.003
+1.6667%
INO
8.58
+0.19
+2.26%
ISCO
0.05
0.00
0.00%
ISIS
66.71
-1.01
-1.49%
LGND
88.15
+0.89
+1.02%
LPTN
0.291
-0.009
-3.032%
MBVX
2.26
-0.08
-3.42%
MEIP
1.89
-0.02
-1.05%
MNOV
3.95
0.00
0.00%
MRTX
36.18
+2.43
+7.20%
MSTX
0.54
+0.03
+5.70%
NBIX
42.76
-0.18
-0.42%
NUVA
49.62
+0.84
+1.72%
ONCS
0.233
0.00
0.00%
ONVO
4.96
+0.17
+3.55%
OREX
4.92
-0.01
-0.20%
OTIC
24.33
-0.13
-0.53%
QDEL
22.24
-0.17
-0.76%
RCPT
164.83
-0.82
-0.50%
RGLS
13.58
-0.05
-0.37%
RMD
58.65
+0.55
+0.95%
SCIE
0.018
0.00
0.00%
SPHS
1.11
+0.03
+2.78%
SRNE
13.8
+0.76
+5.83%
TROV
11
-0.19
-1.70%
VICL
0.955
+0.033
+3.534%
VOLC
17.99
0.00
0.00%
ZGNX
1.49
+0.02
+1.36%
Home » Bio: Joseph E. Payne

Bio: Joseph E. Payne

Joseph E. Payne brings with him an exceptional track record of ushering novel therapeutics to the clinic including successful experience developing sophisticated targeted RNAi nanoparticle technologies.  Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto Denko as evidenced by over 40 publications and patents, and 7 FDA-approved IND clinical candidates.  His academic training includes BYU (magna cum laude, Chemistry and Physics), University of Calgary (Synthetic Organic Chemistry), and MIT Sloan School of Management (Executive Training, Supply Chain and Logistics.